trial

A Study of Lurasidone HCl in Subjects With Schizophrenia

NCTId NCT03393026
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 54 (actual)
Sponsored by Standard Chem. & Pharm. Co., Ltd.
Primary completion 2019-09-17
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
54 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2018-01-03
Primary completion
2019-09-17
Eligibility
ALL · 20 Years · 75 Years

Interventions & indications

Drugs
Lurasidone

Sponsors

Standard Chem. & Pharm. Co., Ltd.Lead Sponsor

Sites

2 total
Taipei, TaiwanTaipei, Taiwan

Facts & assertions

4 sourced
Enrollment
54
Phase
PHASE4
Primary Completion Date
2019-09-17
Status
COMPLETED
relationships
The graph out of here
drug
Lurasidone
drug
lead_sponsor
Standard Chem. & Pharm. Co., Ltd.
company
indication
Schizophrenia
indication
Schizophrenia
indication